The present invention relates to mutant animals having a modified NMDA Receptor and use of the same for screening compounds useful for treating psychiatric and neurological disorders, such as schizophrenia, autism and Alzheimer's Disease. In particular, the invention provides an animal model that has mutation in phosphorylation of the NR1 subunit of the NMDAR, which causes behavioral deficits associated with psychiatric disorders useful for the evaluation of the therapeutic effects of psychotropic drugs for the treatment of these disorders.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS